1592P - Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Immunotherapy
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Karina Silina
Citation Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393
Authors K. Silina1, U. Petrausch2, F. Posch3, S. Leibl4, A. Mündlein5, H. Moch4, A. Siebenhüner6, R. Stupp6, J. Riedl3, B.C. Pestalozzi6, P. Schraml4, A. Gerger3, T. Winder6
  • 1Institute Of Experimental Immunology, University of Zurich, 8057 - Zürich/CH
  • 2Swiss Tumor Immunology Institute, OnkoZentrum Zürich, 8038 - Zürich/CH
  • 3Department Of Internal Medicine, Medical University Graz, 8036 - Graz/AT
  • 4Department Of Pathology, University Hospital Zürich, 8091 - Zürich/CH
  • 5Vivit, Vorarlberg Institute for Vascular Investigation and Treatment, 6800 - Feldkirch/AT
  • 6Oncology, Universitätsspital Zürich, 8091 - Zürich/CH



Tumor immune infiltrates play a critical role in CRC. The neutrophil to lymphocyte ratio (NLR), microsatelite instability (MSI-H), and tertiary lymphoid structures (TLS) have shown independent prognostic value in several cancer types. In this study, we performed molecular, tissue and liquid testing in stage II and III colorectal cancer to link molecular and immunological findings aiming to predict tumor immune infiltrates.


For this retrospective, exploratory study we analyzed prospectively collected archival tissue samples of 111 patients with stage II and III CRC. To quantify TLS/mm at tumor invasive front we performed multispectral microscopy after immunofluorescent co-staining of CD21/CD23. BRAF mutation was determined by allele-specific PCR. MSI was assessed by immunohistochemistry for the mismatch repair proteins MLH1, MSH2, PMS2, MSH6. NLR was defined by absolute peripheral blood neutrophil count divided by the absolute peripheral blood lymphocyte count.


BRAF V600E and MSI-H status were highly associated with each other: 5 (50%) out of the 10 CRC patients with MSI-H had a BRAF mutation (p 


We discovered NLR as a peripheral blood surrogate to identify TLS as part of the tumor immune contexture. For the first time, we linked NLR with immune-related genomic alterations and immune-cell infiltration in stage II and III colorectal cancer.

Clinical trial identification

Legal entity responsible for the study



University Hospital Zurich


All authors have declared no conflicts of interest.